|
64 Companies |
|
21 Products |
|
21 Products |
|
23 Mechanisms of Action |
|
221 Trials |
|
11162 News |
|
| «12...130131132133134135136137138139140141142» |
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) - Feb 12, 2017
P2, N=40, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jun 2017 --> Dec 2017
- New trial: OVEMP in Myasthenia (clinicaltrials.gov) - Feb 10, 2017
P=N/A, N=200, Recruiting, Sponsor: University of Zurich
- | Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Enrollment open: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (clinicaltrials.gov) - Jan 18, 2017
P2, N=24, Recruiting, Sponsor: arGEN-X BVBA
Trial primary completion date: Jun 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
Enrollment status: Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) (clinicaltrials.gov) - Jan 12, 2017
P3, N=28, Recruiting, Sponsor: Catalyst Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Enrolling by invitation --> Recruiting
- Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Trial primary completion date: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Jan 10, 2017
P=N/A, N=4, Terminated, Sponsor: St. Louis University
Enrolling by invitation --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
New P3 trial: Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) (clinicaltrials.gov) - Nov 20, 2016
P3, N=28, Enrolling by invitation, Sponsor: Catalyst Pharmaceuticals, Inc.
- | Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
New P2 trial: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (clinicaltrials.gov) - Nov 17, 2016
P2, N=24, Not yet recruiting, Sponsor: arGEN-X BVBA
- Trial primary completion date: Exercise for Stable Myasthenia Gravis (clinicaltrials.gov) - Oct 31, 2016
P1, N=30, Recruiting, Sponsor: Baltimore VA Medical Center
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2015 --> Dec 2020
- || Rituxan (rituximab) / Roche
New P3 trial: A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis (clinicaltrials.gov) - Oct 31, 2016
P3, N=60, Recruiting, Sponsor: Fredrik Piehl
- || Trial primary completion date: Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis (clinicaltrials.gov) - Oct 17, 2016
P2, N=60, Recruiting, Sponsor: Grifols Therapeutics Inc.
Trial primary completion date: Dec 2015 --> Dec 2020 Trial primary completion date: Jan 2017 --> Dec 2017
- || Clinical: A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) - Oct 3, 2016
P2, N=62, Recruiting, Sponsor: Grifols Therapeutics Inc.
Trial primary completion date: Jan 2017 --> Dec 2017 Trial primary completion date: Aug 2016 --> Apr 2017
- New trial: Tissue Repository for Studies of Myasthenia Gravis (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=300, Recruiting, Sponsor: Johns Hopkins University
- Myasterix (CV-MG01) / CuraVac
Trial primary completion date, IO biomarker: Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) - Sep 14, 2016
P1/2, N=32, Recruiting, Sponsor: CuraVac
Trial primary completion date: Aug 2016 --> Apr 2017 Trial primary completion date: Sep 2016 --> Mar 2017
- Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
Trial completion: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) (clinicaltrials.gov) - Jul 28, 2016
P3, N=38, Completed, Sponsor: Catalyst Pharmaceuticals, Inc.
Trial primary completion date: Sep 2016 --> Mar 2017 Active, not recruiting --> Completed
- | Trial primary completion date: A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations (clinicaltrials.gov) - Jul 27, 2016
P3, N=50, Recruiting, Sponsor: Grifols Therapeutics Inc.
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Jun 2017
- Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
Enrollment change, Trial primary completion date: Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) - Jul 27, 2016
P3, N=20, Recruiting, Sponsor: Catalyst Pharmaceuticals, Inc.
Trial primary completion date: Jul 2016 --> Jun 2017 N=10 --> 20 | Trial primary completion date: May 2016 --> Oct 2017
- ||||| Soliris (eculizumab) / AstraZeneca
Enrollment closed, Enrollment change: Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - Jul 19, 2016
P3, N=117, Active, not recruiting, Sponsor: Alexion Pharmaceuticals
N=10 --> 20 | Trial primary completion date: May 2016 --> Oct 2017 Enrolling by invitation --> Active, not recruiting | N=92 --> 117
- ||||||| Soliris (eculizumab) / AstraZeneca
Trial completion, Enrollment change: Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) (clinicaltrials.gov) - Jul 19, 2016
P3, N=125, Completed, Sponsor: Alexion Pharmaceuticals
Enrolling by invitation --> Active, not recruiting | N=92 --> 117 Active, not recruiting --> Completed | N=92 --> 125
- Trial termination, Trial primary completion date: Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis (clinicaltrials.gov) - Jul 19, 2016
P1, N=9, Terminated, Sponsor: Northwestern University
Active, not recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2016; No participants enrolled for more than two years. No plan to continue study.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) - Jun 11, 2016
P2, N=40, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
No plan to continue study. N=20 --> 40
- ||| Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
New P3 trial: A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) (clinicaltrials.gov) - May 18, 2016
P3, N=30, Recruiting, Sponsor: University of Alberta
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis (clinicaltrials.gov) - May 5, 2016
P2, N=50, Active, not recruiting, Sponsor: Yale University
N=20 --> 40 Recruiting --> Active, not recruiting
- Biomarker, New trial: Biomarkers in Neural Disorders (clinicaltrials.gov) - May 4, 2016
P=N/A, N=270, Not yet recruiting, Sponsor: University of Pennsylvania
- Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Trial primary completion date: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=4, Terminated, Sponsor: St. Louis University
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Dec 2016
- | iscalimab (CFZ533) / Novartis
Enrollment open: Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis (clinicaltrials.gov) - Jan 26, 2016
P2, N=44, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
Enrollment open, Trial initiation date: Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) - Jan 26, 2016
P3, N=10, Recruiting, Sponsor: Catalyst Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Jan 2016
- | Benlysta (belimumab) / GSK
Trial completion, Enrollment change: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Jan 25, 2016
P2, N=40, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Jan 2016 Active, not recruiting --> Completed | N=60 --> 40
- Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Trial primary completion date: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Jan 25, 2016
P=N/A, N=4, Terminated, Sponsor: St. Louis University
Active, not recruiting --> Completed | N=60 --> 40 Trial primary completion date: Dec 2015 --> Mar 2016
- Trial primary completion date: The Role of the Thymus in Myasthenia Gravis (clinicaltrials.gov) - Jan 21, 2016
P=N/A, N=80, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Myasterix (CV-MG01) / CuraVac
New P1/2 trial, IO biomarker: Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) - Nov 21, 2015
P1/2, N=32, Recruiting, Sponsor: CuraVac
- | iscalimab (CFZ533) / Novartis
New P2 trial: Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis (clinicaltrials.gov) - Oct 1, 2015
P2, N=44, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
New P3 trial: Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) - Sep 29, 2015
P3, N=10, Not yet recruiting, Sponsor: Catalyst Pharmaceuticals, Inc.
- Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Trial primary completion date: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Sep 28, 2015
P=N/A, N=4, Terminated, Sponsor: St. Louis University
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Aug 2015 --> Dec 2015
- prednisone / Generic mfg.
Trial primary completion date: Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy (clinicaltrials.gov) - Sep 21, 2015
P3, N=126, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Aug 2015 --> Dec 2015 Trial primary completion date: Aug 2015 --> Nov 2015
- ||||| Soliris (eculizumab) / AstraZeneca
Enrollment closed: Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) (clinicaltrials.gov) - Sep 14, 2015
P3, N=92, Active, not recruiting, Sponsor: Alexion Pharmaceuticals
Trial primary completion date: Aug 2015 --> Nov 2015 Recruiting --> Active, not recruiting
- ||| Benlysta (belimumab) / GSK
Enrollment change: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Aug 17, 2015
P2, N=60, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting N=40 --> 60
- Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Enrollment change, Trial termination, Trial primary completion date: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=4, Terminated, Sponsor: St. Louis University
N=40 --> 60 N=10 --> 4 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Aug 2015; Study stopped by sponsor due to difficulty enrolling at site
- |||| Clinical: A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jul 29, 2015
P2, N=62, Recruiting, Sponsor: Grifols Therapeutics Inc.
N=10 --> 4 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Aug 2015; Study stopped by sponsor due to difficulty enrolling at site Not yet recruiting --> Recruiting
- Trial primary completion date: A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations (clinicaltrials.gov) - Jul 16, 2015
P3, N=50, Recruiting, Sponsor: Grifols Therapeutics Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Jul 2016
- | Trial completion, Trial primary completion date: Therapeutic Plasma Exchange in MG (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=11, Completed, Sponsor: Duke University
Trial primary completion date: Sep 2015 --> Jul 2016 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Oct 2014
- ||||| New P2 trial: A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jun 17, 2015
P2, N=62, Not yet recruiting, Sponsor: Grifols Therapeutics Inc.
- ||||| New P2 trial: Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jun 17, 2015
P2, N=60, Recruiting, Sponsor: Grifols Therapeutics Inc.
- New trial: Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F (clinicaltrials.gov) - Jun 12, 2015
P=N/A, N=120, Completed, Sponsor: Assistance Publique - H
- | Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Enrollment open: Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis (clinicaltrials.gov) - Apr 29, 2015
P2, N=25, Recruiting, Sponsor: Mazen Dimachkie, MD
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Oct 2014 Not yet recruiting --> Recruiting
- ||||||| tacrolimus oral / Generic mfg.
Trial completion: A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis (clinicaltrials.gov) - Apr 27, 2015
P3, N=83, Completed, Sponsor: Astellas Pharma Inc
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial primary completion date: Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis (clinicaltrials.gov) - Apr 19, 2015
P1, N=10, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Trial primary completion date: Feb 2015 --> Feb 2017
- Trial termination: Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=100, Terminated, Sponsor: University of Texas
Trial primary completion date: Feb 2015 --> Feb 2017 Active, not recruiting --> Terminated
- ||| New P3 trial: A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations (clinicaltrials.gov) - Apr 10, 2015
P3, N=50, Recruiting, Sponsor: Grifols Therapeutics Inc.
- | Benlysta (belimumab) / GSK
Enrollment closed: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Mar 18, 2015
P2, N=40, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- | New P4 trial: The effect of tetanus revaccination in patients with myasthenia gravis Het effect of tetanus revaccinatie in patienten met myasthenia gravis. (EUDRACT) - Feb 20, 2015
P4, N=80, Ongoing, Sponsor: Leiden University Medical Center